# Third Rock Ventures

> Third Rock Ventures is a VC fund backing Biotechnology and Health Care. See 173 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 173
- Last investment: Jun 2026
- Lead investor: 47%
- Last fund: Jun 2022
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/third-rock-ventures
- Website: http://www.thirdrockventures.com

Third Rock Ventures is a VC fund in Boston focused on Biotechnology and Health Care. Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

## Contacts

5 contacts available for Third Rock Ventures. Shizune tracks 22 team members at Third Rock Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/third-rock-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $19M–$110M |
| Series B | $11M–$190M |
| Series C | $20M–$108M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 63 | 36% |
| Health Care | 39 | 23% |
| Therapeutics | 34 | 20% |
| Medical | 26 | 15% |
| Pharmaceutical | 17 | 10% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 60 | 35% |
| Series B | 38 | 22% |
| Series C | 15 | 9% |
| Series D | 4 | 2% |
| Funding Round | 4 | 2% |

10 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Cary Pfeffer | Partner | 9 | https://shizune.co/investors/profile/cary-pfeffer |
| Jeff Tong | Partner | 2 | https://shizune.co/investors/profile/jeff-tong |
| Jigar Raythatha | Partner | 2 | https://shizune.co/investors/profile/jigar-raythatha |
| Mark Levin | Partner | 5 | https://shizune.co/investors/profile/mark-levin |
| Reid Huber | Partner | 12 | https://shizune.co/investors/profile/reid-huber |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Flare Therapeutics | Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M | Series C | Jun 30, 2026 |  |
| Flare Therapeutics | Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M | Series C | Jun 30, 2026 |  |
| Terremoto Biosciences | Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $108M | Series C | Apr 15, 2026 |  |
| Terremoto Biosciences | Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $108M | Series C | Apr 15, 2026 |  |
| Syremis Therapeutics | Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders. | $165M | Series A | Dec 18, 2025 |  |
| Azalea Therapeutics | Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $65M | Series A | Nov 04, 2025 |  |
| Azalea Therapeutics | Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $65M | Series A | Nov 04, 2025 |  |
| Azalea Therapeutics | Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $17M | Seed | Nov 04, 2025 |  |
| ARTBIO | ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $132M | Series B | Jul 29, 2025 |  |
| Corvia Medical | Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts. | $55M |  | Jun 17, 2025 |  |

10 of 173 investments shown.

## Co-investors
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 24 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 22 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 20 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 19 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 18 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 16 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)
- [Health Care Investors in United States](https://shizune.co/investors/health-care-investors-united-states)
- [Health Care VC Funds in United States](https://shizune.co/investors/health-care-vc-funds-united-states)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)

## FAQ

### What does Third Rock Ventures invest in?

Third Rock Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 173 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Third Rock Ventures's check size?

Third Rock Ventures typically joins rounds of $19M–$110M at Series A, $11M–$190M at Series B and $20M–$108M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Third Rock Ventures participates in.

### How do I contact Third Rock Ventures?

Public channels for Third Rock Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Third Rock Ventures?

The team at Third Rock Ventures includes Cary Pfeffer (Partner), Jeff Tong (Partner) and Jigar Raythatha (Partner), among 22 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co